Revenue · 2020–2025
Xeris Biopharma revenue
$292M+43.7% · FY2025
Xeris Biopharma (XERS) reported $292M in revenue for fiscal 2025, +43.7% year on year.
Revenue — Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2020–2025 compound annual growth +70.2%
Revenue at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Xeris Biopharma revenue |url=https://companiesranked.com/en/company/xeris-biopharma/revenue |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Xeris Biopharma revenue. CompaniesRanked. https://companiesranked.com/en/company/xeris-biopharma/revenueBibTeX
@misc{companiesranked-en-company-xeris-biopharma-revenue-2026,
author = {{CompaniesRanked}},
title = {{Xeris Biopharma revenue}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/xeris-biopharma/revenue}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001867096-26-000016 · March 2, 2026
{{cite web |title=Xeris Biopharma revenue — 10-K (0001867096-26-000016) |url=https://www.sec.gov/Archives/edgar/data/1867096/000186709626000016/xers-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-02}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.